NCT07755904RecruitingPhase 3
BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Phase 3, Multi-region, Multi-center, Randomized, Double-blind, Active-Comparator-Controlled Trial to Evaluate the Efficacy and Safety of BHB-1893 Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Source: ClinicalTrials.gov · Last updated 2 Oct 2026
Brief summary (registry, in English)
The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM). The trial includes adults who are currently being treated for oHCM or who have not yet been treated.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 210 (estimated)
- First submitted
- 5 Aug 2026
- Start date
- 2 Sept 2026
- Primary completion date
- Oct 2028
- Lead sponsor
- Braveheart Bio, Inc.
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT07755904
- EU CT number
- 2026-526007-30-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 210
- From 2 Sept 2026 to the primary completion date, Oct 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of intolerance or medical contraindication to β-blocker therapy
- Resting heart rate of \>100 beats per minute (bpm) at screening visits
- Significant valvular heart disease, defined as:
- Moderate to severe valvular aortic stenosis or fixed subaortic obstruction;
- Mitral regurgitation not due to systolic anterior motion of the mitral valve (per Investigator's judgment)
- Other protocol-defined criteria apply.
Lab values
- Medical indication for either β-blocker or calcium-channel blocker therapy, other than oHCM, prohibiting drug discontinuation
Other
- Resting systolic blood pressure (SBP) of \>160 millimeters of mercury (mmHg) at screening visits
Who the study is looking for
- Diagnosed with oHCM per the protocol specified criteria
- NYHA Class II or III at screening visits
- KCCQ-CSS that meets the protocol specified criteria at screening visits
- Adequate acoustic windows for echocardiography
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Manhasset | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Plano | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Rock Hill | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.